

**PRODUCT INFORMATION**

<b>Common Name</b>	Icatolimab;JS-004;JS004;JS 004;JS-4;JS4;JS 4;TAB-004;TAB004;TAB 004;TAB-4;TAB4;TAB 4
<b>Conjugate</b>	PE-conjugated
<b>Synonyms</b>	BTLA;BTLA1;CD272
<b>Applications</b>	Flow Cyt
<b>Recommended Dilutions</b>	Flow Cyt 1:100
<b>Formulation &amp; Reconstitution</b>	Liquid□PBS with 0.05% Proclin300, 1% BSA
<b>Host Species</b>	N/A
<b>IgG type</b>	IgG4
<b>Reactivity</b>	Human
<b>Target</b>	BTLA
<b>Uniprot ID</b>	Q7Z6A9
<b>Description</b>	PE-conjugated Anti-BTLA(tifcemalimab biosimilar) mAb
<b>Delivery</b>	Under Development
<b>Storage &amp; Shipping</b>	Store at 2°C-8°C for 6 months
<b>Background</b>	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
<b>Usage</b>	Research use only
<b>DIMA Disclaimer</b>	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

